Personalized medicine and proteomics: lessons from non-small cell lung cancer.
about
Multidimensional proteomics analysis of amniotic fluid to provide insight into the mechanisms of idiopathic preterm birthUtilizing the molecular gateway: the path to personalized cancer management.Proteomic biomarkers for acute interstitial lung disease in gefitinib-treated Japanese lung cancer patientsMoving towards high density clinical signature studies with a human proteome catalogue developing multiplexing mass spectrometry assay panels.Biobank resources for future patient care: developments, principles and concepts.State-of-the-art MS technology applications in lung disease.PTRF/cavin-1 and MIF proteins are identified as non-small cell lung cancer biomarkers by label-free proteomics.Understanding drug uptake and binding within targeted disease micro-environments in patients: a new tool for translational medicine.Identification of α1-antitrypsin as a potential prognostic biomarker for advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors by proteomic analysis.Clinical initiatives linking Japanese and Swedish healthcare resources on cancer studies utilizing Biobank Repositories.Cancer Phenotype Diagnosis and Drug Efficacy within Japanese Health Care.Proteomics of the human placenta: promises and realities.Maternal vitamin D deficiency and fetal distress/birth asphyxia: a population-based nested case-control study.Comparative analysis of the liver and plasma proteomes as a novel and powerful strategy for hepatocellular carcinoma biomarker discovery.A reevaluation of the clinical significance of histological subtyping of non--small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments.Personalized medicine in oncology: tailoring the right drug to the right patient.Abnormal levels of heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) in tumour tissue and blood samples from patients diagnosed with lung cancer.Functional proteomics outlines the complexity of breast cancer molecular subtypes.A selected reaction monitoring mass spectrometric assessment of biomarker candidates diagnosing large-cell neuroendocrine lung carcinoma by the scaling method using endogenous references.Building the basis for proteomics in personalized medicine for targeted treatment.Predicting the future for people with lung cancer.Identification by differential tissue proteome analysis of talin-1 as a novel molecular marker of progression of hepatocellular carcinoma.Urothelial cancer proteomics provides both prognostic and functional information.
P2860
Q28472589-EFCEB79C-36E0-4596-ACB0-421A39BC12B2Q30371443-467DEBA9-F7D1-444F-9086-184E14328025Q31026775-14DA0C3A-421D-4E87-8DF5-CDECC856A5AFQ34008044-F63FB225-C329-4F0F-AD30-71ADA0AB1F76Q34020952-5A986962-F4FC-4853-B758-79FFDA0DB193Q34089332-B6406C5B-40DE-4E17-B63B-4670C8482CEBQ34213807-61E3BCE8-CC92-4671-8DF9-46151BA5991DQ34570198-5973B835-1FA5-496B-B8C7-C88582853AC9Q34683513-4362EFA4-EF63-4632-A3F8-FC71CF9BC2A6Q35003244-744DBAFA-22D4-4F75-B808-3950FD1712CDQ35999625-3BAB0620-7148-4CF4-B127-798295A4D1A9Q36197254-760B3E1F-55EF-4DCC-9B75-37C96897B696Q37312174-34C226A3-8526-44BE-A3D3-990A9FA1C82DQ37397825-92C70622-04B2-477D-9D92-830D896C4C61Q37483162-8FF827F2-2D85-4728-AB79-880ACC302312Q37779306-05D50F5B-44B0-4FD5-A855-FF17420A8BBEQ38931288-E27FEB71-B888-4147-B6A6-D919579544EAQ41564586-FE7D84C3-C347-4E60-B4D5-B21C3D61179BQ42290338-D95B7A11-D315-480D-9D13-49F66D3422C2Q42575186-F3A58E30-15D7-4308-890F-8F53D9BC4B11Q42878612-55B05420-C9F4-4F5B-BAD5-C5A364804218Q44419410-003E69A2-7AF6-4459-A03F-A21E34E80E1AQ47156880-2E6B8061-C95B-48AE-AB40-ECE4D5D7188F
P2860
Personalized medicine and proteomics: lessons from non-small cell lung cancer.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Personalized medicine and proteomics: lessons from non-small cell lung cancer.
@ast
Personalized medicine and proteomics: lessons from non-small cell lung cancer.
@en
Personalized medicine and proteomics: lessons from non-small cell lung cancer.
@nl
type
label
Personalized medicine and proteomics: lessons from non-small cell lung cancer.
@ast
Personalized medicine and proteomics: lessons from non-small cell lung cancer.
@en
Personalized medicine and proteomics: lessons from non-small cell lung cancer.
@nl
prefLabel
Personalized medicine and proteomics: lessons from non-small cell lung cancer.
@ast
Personalized medicine and proteomics: lessons from non-small cell lung cancer.
@en
Personalized medicine and proteomics: lessons from non-small cell lung cancer.
@nl
P2093
P356
P1476
Personalized medicine and proteomics: lessons from non-small cell lung cancer.
@en
P2093
Atsushi Ogiwara
Chris G Harbron
Fredrik Nyberg
Haiyi Jiang
Harubumi Kato
Hideo Kunito
Hisae Anyoji
Hsiao-Kun Tu
Ian S Peers
Kazuto Nishio
P304
P356
10.1021/PR070046S
P577
2007-07-17T00:00:00Z